Patents by Inventor Nazareno Paolocci
Nazareno Paolocci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240109937Abstract: The invention provides isolated AIF and PPIA binding peptides that disrupt PPIA/AIF complex formation and/or activity and prevent the resulting death of myocardial cells and to pharmaceutical compositions thereof. The invention further provides uses of the isolated peptides in methods of preventing myocardial cell death and/or sudden cardiac death in subject.Type: ApplicationFiled: February 7, 2022Publication date: April 4, 2024Inventors: Stephen P. Chelko, Nazareno Paolocci, Daniel P. Judge, Gizem Keceli, Peter Andersen, Nuria Amat, Nunzianna Doti, Menotti Ruvo, Alessandra Monti
-
Patent number: 11235029Abstract: The present invention relates to compositions and methods for the treatment of heart failure.Type: GrantFiled: March 9, 2018Date of Patent: February 1, 2022Assignees: Temple University-Of The Commonwealth System of Higher, Education Johns Hopkins Technology Ventures, Universita di Napoli Federico IIInventors: Alessandro Cannavo, Ning Feng, Giuseppe Rengo, Nazareno Paolocci, Walter J. Koch
-
Patent number: 10786543Abstract: The present invention provides 75 kD transmembrane neurotrophin receptor (p75NTR) antagonists and their use in prevention and treatment of loss of function, and adverse remodeling, in cardiac tissues subject to acute or chronic hemodynamic stress. Uses of the antagonists with or without additional cardiotropic agents for improving contractility and for treatment of congestive heart failure are also provided.Type: GrantFiled: September 22, 2016Date of Patent: September 29, 2020Assignees: The Johns Hopkins University, Vanderbilt UniversityInventors: Nazareno Paolocci, Ning Feng, Carlo G. Tocchetti, Cyrus Takahashi, Bruce Carter
-
Publication number: 20180271931Abstract: The present invention provides 75 kD transmembrane neurotrophin receptor (p75NTR) antagonists and their use in prevention and treatment of loss of function, and adverse remodeling, in cardiac tissues subject to acute or chronic hemodynamic stress. Uses of the antagonists with or without additional cardiotropic agents for improving contractility and for treatment of congestive heart failure are also provided.Type: ApplicationFiled: September 22, 2016Publication date: September 27, 2018Inventors: Nazareno Paolocci, Ning Feng, Carlo G. Tocchetti, Cyrus Takahashi, Bruce Carter
-
Publication number: 20180256683Abstract: The present invention relates to compositions and methods for the treatment of heart failure.Type: ApplicationFiled: March 9, 2018Publication date: September 13, 2018Inventors: Alessandro Cannavo, Ning Feng, Giuseppe Rengo, Nazareno Paolocci, Walter J. Koch
-
Publication number: 20160228460Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO· donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: ApplicationFiled: April 20, 2016Publication date: August 11, 2016Inventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
-
Publication number: 20160166604Abstract: The present invention relates to methods for treating diastolic dysfunction or a disease, disorder or condition associated with diastolic dysfunction, methods for treating heart failure, methods for modulating SR Ca2+ release and/or uptake, methods for enhancing myocyte relaxation, preload or E2P hydrolysis, and methods for treating ventricular hypertrophy.Type: ApplicationFiled: March 9, 2015Publication date: June 16, 2016Inventors: Nazareno Paolocci, David A. Kass, Carlo G. Tocchetti
-
Publication number: 20150011643Abstract: Administration of monoamine oxidase inhibitors is useful in the prevention and treatment of heart failure and incipient heart failure.Type: ApplicationFiled: July 15, 2014Publication date: January 8, 2015Inventors: Fabio DiLisa, Ning Feng, Nina Kaludercic, Nazareno Paolocci
-
Publication number: 20150004259Abstract: Administration of an HNO/NO+ donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO? donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: ApplicationFiled: September 17, 2014Publication date: January 1, 2015Inventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
-
Patent number: 8268890Abstract: Nitroxyl donating compounds are administered prior to the onset of ischemia for the prevention and/or reduction of ischemia/reperfusion injury in subjects at risk for ischemia. Nitroxyl donors also are administered to organs to be transplanted for the prevention and/or reduction of ischemia/reperfusion injury upon reperfusion in a recipient. Nitroxyl donors include any nitroxyl donating compound. In particular cases the nitroxyl donor is a nitroxyl-donating diazeniumdiolate, such as Angeli's salt or IPA/NO.Type: GrantFiled: December 30, 2008Date of Patent: September 18, 2012Assignees: Johns Hopkins University, The United States of America as represented by the Secretary of Health and Human Services, The Regents of the University of CaliforniaInventors: David A. Wink, Martin Feelisch, Pasquale Pagliaro, David A. Kass, Nazareno Paolocci, Katrina M. Miranda, Jon M. Fukuto
-
Publication number: 20120231482Abstract: A method of screening for compounds that enhance or depress contractile function, based on measuring the formation of heterodimers of contractile fibers (e.g. Tm and actin, myosin heavy and myosin light chains), for example through disulfide bond formation. Diagnostic and prognostic methods and kits are also provided.Type: ApplicationFiled: November 15, 2010Publication date: September 13, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Christopher I. Murray, Jennifer E. Van Eyk, Nazareno Paolocci, Wei Dong Gao, Darren Brian Foster
-
Publication number: 20120201907Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: ApplicationFiled: April 13, 2012Publication date: August 9, 2012Applicants: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Johns Hopkins University, The Regents of the University of California, Government of the USA represented by the Secretary of the Department of Health and Human ServicesInventors: David A. WINK, Martin FEELISCH, David A. KASS, Nazareno PAOLOCCI, Katrina MIRANDA, Jon FUKUTO, Tatsuo KATORI
-
Publication number: 20110081427Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO? donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: ApplicationFiled: November 18, 2010Publication date: April 7, 2011Applicants: The Government of the U.S.A. as represented by the Secretary of the Dept. of Health and Human Servic, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, The Regents of the University of California, Johns Hopkins UniversityInventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
-
Patent number: 7863262Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO(Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO? donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: GrantFiled: March 31, 2005Date of Patent: January 4, 2011Assignees: Johns Hopkins University, The United States of America as represented by the Department of Health and Human Services, The Regents of the University of California, The Board of Supervisors of Louisiana State University and Agriculture and Mechanical CollegeInventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
-
Publication number: 20090298795Abstract: The present invention relates to methods for treating diastolic dysfunction or a disease, disorder or condition associated with diastolic dysfunction, methods for treating heart failure, methods for modulating SR Ca2+ release and/or uptake, methods for enhancing myocyte relaxation, preload or E2P hydrolysis, and methods for treating ventricular hypertrophy.Type: ApplicationFiled: June 23, 2006Publication date: December 3, 2009Applicant: THE JOHNS HOPINS UNIVERSITYInventors: Nazareno Paolocci, David A. Kass, Carlo G. Tocchetti
-
Publication number: 20090286883Abstract: Administration of monoamine oxidase inhibitors is useful in the prevention and treatment of heart failure and incipient heart failure.Type: ApplicationFiled: March 19, 2009Publication date: November 19, 2009Applicants: Universita' degli Studi di Padova (University of Padua)Inventors: Fabio DiLisa, Ning Feng, Nina Kaludercic, Nazareno Paolocci
-
Publication number: 20090280194Abstract: Compositions and methods for treating hormone dependent or independent cancers overexpressing MAT-8 in a patient by administration of nitroxyl-donating compounds and treating patient suffering from cancers such as prostate cancer, breast cancer, pancreatic cancer, colon cancer and lung cancer.Type: ApplicationFiled: May 7, 2008Publication date: November 12, 2009Inventors: Jeffrey P. FROEHLICH, Nazareno PAOLOCCI
-
Publication number: 20090246296Abstract: Nitroxyl donating compounds are administered prior to the onset of ischemia for the prevention and/or reduction of ischemia/reperfusion injury in subjects at risk for ischemia. Nitroxyl donors also are administered to organs to be transplanted for the prevention and/or reduction of ischemia/reperfusion injury upon reperfusion in a recipient. Nitroxyl donors include any nitroxyl donating compound. In particular cases the nitroxyl donor is a nitroxyl-donating diazeniumdiolate, such as Angeli's salt or IPA/NO.Type: ApplicationFiled: December 30, 2008Publication date: October 1, 2009Inventors: David A. Wink, Martin Feelisch, Pasquale Pagliaro, David A. Kass, Nazareno Paolocci, Katrina M. Miranda, Jon M. Fukuto
-
Publication number: 20050192254Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO(Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO+ donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: ApplicationFiled: March 31, 2005Publication date: September 1, 2005Inventors: David Wink, Martin Feelisch, David Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
-
Patent number: 6936639Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt.Type: GrantFiled: August 21, 2002Date of Patent: August 30, 2005Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, The Regents of the University of California, Johns Hopkins University, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Louisiana State University Health Sciences CenterInventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori